Consolidated Statement Of Cash Flows

Modalis Therapeutics Corporation - Filing #7591582

Concept 2022-01-01 to
2022-06-30
As at
2022-06-30
As at
2021-12-31
As at
2021-06-30
2021-01-01 to
2021-06-30
As at
2020-12-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-780,483,000 JPY
20,899,000 JPY
Depreciation
58,358,000 JPY
36,622,000 JPY
Interest and dividend income
-27,000 JPY
-27,000 JPY
Interest expenses
2,331,000 JPY
JPY
Foreign exchange losses (gains)
-64,452,000 JPY
-6,128,000 JPY
Increase (decrease) in provision for bonuses
13,839,000 JPY
JPY
Subtotal
-708,650,000 JPY
-466,527,000 JPY
Income taxes paid
-1,210,000 JPY
-1,210,000 JPY
Net cash provided by (used in) operating activities
-713,384,000 JPY
18,377,000 JPY
Other, net
8,401,000 JPY
-38,551,000 JPY
Interest and dividends received
27,000 JPY
27,000 JPY
Interest paid
-3,551,000 JPY
JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-129,719,000 JPY
-5,620,000 JPY
Net cash provided by (used in) investing activities
-118,965,000 JPY
275,022,000 JPY
Other, net
JPY
319,000 JPY
Cash flows from financing activities
Net cash provided by (used in) financing activities
3,653,000 JPY
56,436,000 JPY
Other, net
-267,000 JPY
JPY
Effect of exchange rate change on cash and cash equivalents
50,993,000 JPY
13,267,000 JPY
Net increase (decrease) in cash and cash equivalents
-777,701,000 JPY
363,103,000 JPY
Cash and cash equivalents
4,158,491,000 JPY
4,936,193,000 JPY
5,784,579,000 JPY
5,421,476,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.